Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR. Methods: We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers. Results: BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive. Conclusions: The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival. (Clin Mol Hepatol 2016;22:366-371)
Abstract
Background/Aims: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR. Methods: We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers. Results: BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive. Conclusions: The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival. (Clin Mol Hepatol 2016;22:366-371)
참고문헌 (20)
- Hai-Rim Shin, "The Prevalence of Hepatitis C Virus Infection in Korea: Pooled Analysis", Journal of Korean Medical Science, 20(6), pp.985~988 (2005), 대한의학회
- Viral hepatitis surveillance system and statue of C hepatitis sentinel surveillance in Korea, "Kim SJ.", KCDC, 214~219, pp.Public Health Weekly Report 5 (2012)
- Gane EJ, "A longitudinal analysis of hepatitis C virus replication following liver transplantation", Gastroenterology, 110, pp.167~177 (1996)
- Howell J, "Hepatitis C recurrence: the Achilles heel of liver transplantation", Transpl Infect Dis, 16, pp.1~16 (2014)
- Gordon SC, "Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease", Aliment Pharmacol Ther, 38, pp.784~793 (2013)
- Berenguer M, "Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment", J Hepatol, 58, pp.1028~1041 (2013)
- Shaked A, "Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation", Am J Transplant, 9, pp.301~308 (2009)
- Shetty S, "Post-transplant liver biopsy and the immune response: lessons for the clinician", Expert Rev Clin Immunol, 8, pp.645~661 (2012)
- Banff Working Group on Liver Allograft Pathology, "Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance", Liver Transpl, 18, pp.1154~1170 (2012)
- Samonakis DN, "Immunosuppression and HCV recurrence after liver transplantation", J Hepatol, 56, pp.973~983 (2012)
- Mitchell O, "Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review", J Clin Transl Hepatol, 3, pp.140~148 (2015)
- Berenguer M, "Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection", J Hepatol, 28, pp.756~763 (1998)
- Terrault N., "Liver transplantation in the setting of chronic HCV", Best Pract Res Clin Gastroenterol, 26, pp.531~548 (2012)
- O’Grady JG, "UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial", Lancet, 360, pp.1119~1125 (2002)
- Adams DH, "From immunosuppression to tolerance", J Hepatol, 62(1 Suppl), pp.S170~S185 (2015)
- Watashi K, "Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes", Hepatology, 38, pp.1282~1288 (2003)
- Martin P, "Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial", Liver Transpl, 10, pp.1258~1262 (2004)
- Berenguer M, "Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis", Liver Transpl, 13, pp.21~29 (2007)
- Watt KD, "Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database", Liver Transpl, 18, pp.1029~1036 (2012)
- Ramirez CB, "Anti- IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months", J Surg Res, 138, pp.198~204 (2007)